Health Condition 1: F209- Schizophrenia, unspecified
Conditions
Interventions
Intervention1: Interventional trial- Randomized controlled trial: The study consists of schizophrenic patients. Each patient is required to be monitored for 4 times i.e. baseline, 4th , 8th and 12th m
Sponsors
Dr Deepak C G
Eligibility
Inclusion criteria
Inclusion criteria: Patient or caretaker Patient or caretaker willing to provide informed consent Patients aged � 18 and � 65 years old Patients diagnosed with schizophrenia and schizophrenia spectrum disorders who were on the treatment of antipsychotic drugs with or without co-morbidities of hypertension, diabetes, hypercholesterolemia and weight gain Both genders
Exclusion criteria
Exclusion criteria: Patient or caretaker unwilling to provide consent Patients with other severe chronic medical conditions, including cancer, end-stage renal disease, heart failure and HIV Patients with a diagnosis of Cushing syndrome, hypothyroidism, eating disorder Patients who are engaged in the weight management programs within the past 3 months Patients who are taking other forms of medicines to control weight including Ayurvedha, Homeopathy Patients with co-existing physical illnesses that reduce their ability to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Impact of pharmaceutical care in improvement or prevention cardiometabolic diseases in schizophrenia by controlling weight gain & obesity will be studiedTimepoint: 0 4 8 12 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes: Measurement of medication adherence, quality of life and comparing the economic burden of schizophrenic patients by cost of illness studyTimepoint: 0 4 8 12 months | — |
Countries
India
Contacts
Public ContactDr Juno J Joel
KS Hegde medical Academy
Outcome results
None listed